Abstract: A system and method for estimating a location of an object or vehicle is provided. Images of a region encompassing the object are obtained, providing a three dimensional (3-D) view frame of the region. 3-D view frames are collected along a direction of travel of the object. A 3-D map is generated along the direction of travel of the object, the map based on the 3-D view frames and further based on an estimate of motion of the object at times associated with the 3-D view frames. A first set of features is extracted from the 3-D map. A geo-referenced feature database is searched for a second set of features that match the first set of features. A geo-location associated with the second set of features is retrieved from the feature database. The location of the object is estimated based on the retrieved geo-location.

Abstract: The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.

Abstract: A system and method for estimating a location of an object or vehicle is provided. Images of a region encompassing the object are obtained, providing a three dimensional (3-D) view frame of the region. 3-D view frames are collected along a direction of travel of the object. A 3-D map is generated along the direction of travel of the object, the map based on the 3-D view frames and further based on an estimate of motion of the object at times associated with the 3-D view frames. A first set of features is extracted from the 3-D map. A geo-referenced feature database is searched for a second set of features that match the first set of features. A geo-location associated with the second set of features is retrieved from the feature database. The location of the object is estimated based on the retrieved geo-location.

Abstract: A system for projecting a first image stream containing a first set of frames for displaying primary content and a second image stream containing a second set of frames that contain alternate content and for allowing a user to configure passive filters to alternate between viewing the first image stream and the second image stream.

Abstract: The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.

Abstract: The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.

Abstract: The present invention relates generally to pharmaceutical formulations of conjugated oligonucleotides, such as pegylated aptamers, as well as to a method of preparing and using the same. The pharmaceutical formulations have desirable shelf life characteristics under varied storage conditions. Formulations of oligonucleotides or oligonucleotides conjugates and methods for their preparation and use are provided having a shelf life of at least about 24 months or, more preferably, at least about 36 months at about 2 to about 30° C. In particular embodiments, the formulations have a pH of about 7 or less and contain methionine. Optionally, dissolved oxygen content is reduced during the manufacturing process is used to improve desired shelf life characteristics.

Abstract: The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.

Abstract: The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.

Abstract: The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.

Abstract: A method for preparing a therapeutic pegylated oligonucleotide is described. The method involves synthesis, cleavage and purification steps designed to improve the efficiency whereby the therapeutic oligonucleotide may be prepared. Also described are methods for large scale preparation at the improved efficiency.

Abstract: A reinforced conveyor belt has a plurality of fabric plies. One of the plies is an interwoven ply comprised of two layers of weft cords and a plurality of warp cords interweaving through the two layers of weft cords. Each warp cord has the following repeating weave pattern of passing over at least two but not more than five weft cords in the first weft layers, passing between the two weft layers for a distance of at least two weft cords, and passing under at least two but nor more than five weft cords in the second weft layer.

Abstract: Techniques are presented for managing fraud information. Metadata defines user profiles, security levels, fraud cases, and presentation information. One or more queries or reports are processed against disparate data store tables and the results are aggregated into a repository. The repository is also defined by the metadata. Furthermore, operations associated with sharing, viewing, and accessing the results from the repository is defined and controlled by the metadata. In an embodiment, portions of the metadata may be viewed and navigated in a hierarchical and graphical formatted presentation.

Abstract: The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.

Abstract: A magnetic fluid rotary feedthrough has a multi-stage magnetic fluid rotary seal adapted to provide a magnetic fluid seal about a shaft for extending between a first environment and a second environment, one or more sensors integrally mounted within the magnetic fluid rotary feedthrough to sense one or more physical parameters of the multi-stage magnetic fluid rotary seal, signal processing electronics mounted to or incorporated in the magnetic fluid rotary feedthrough to receive one or more sensor output signals from the one or more sensors, to process the one or more sensor output signals and to output one or more electronic processing signals, and one or more output devices operatively connected to receive the one or more electronic processing signals from the signal processing electronics to indicate the condition of the multi-stage magnetic fluid rotary seal.

Abstract: A reinforced conveyor belt has a plurality of fabric plies. One of the plies is an interwoven ply comprised of two layers of weft cords and a plurality of warp cords interweaving through the two layers of weft cords. Each warp cord has the following repeating weave pattern of passing over at least two but not more than five weft cords in the first weft layers, passing between the two weft layers for a distance of at least two weft cords, and passing under at least two but nor more than five weft cords in the second weft layer.

Abstract: Woven reinforcing fabrics for such conveyor belts characterized by an improved resistance to tearing in the longitudinal or travel direction. The woven reinforcing fabric includes a plurality of weft yarns and a plurality of warp yarns aligned substantially orthogonal to the plurality of weft yarns. The warp yarns are woven through the weft yarns to define a plurality of passages arranged in substantially parallel first and second planes. At least one of the weft yarns is positioned in each of the passages and two of the weft yarns are positioned in at least one of the passages in each of the first and second planes.

Abstract: Multiplexing bead technology is used for simultaneous screening of multiple LSD and normalizing measured enzyme activity or protein levels against other lysosomal proteins, enzymes, or enzyme activities. Diagnostic compositions include microspheres conjugated to purified antibodies that specifically bind LSD target antigens: saposin, LAMP-1, ?-iduronidase, ?-glucosidase, ?-glucosidase, 2-sulphatase, 4-sulphatase, ?-galactosidase, sphingomyelinase, 3-sulphatase or sulphamidase. The target antigens are naturally present in biological fluids or tissues of either LSD or non-LSD patients.

Abstract: A novel protein profiling method of testing for Lysosomal Storage Diseases (“LSD”) using discovered normalized lysosomal fingerprint patterns. The fingerprint patterns reveal the health of lysosomal organelles, specific LSD, and clinical severity Multiplexing bead technology for simultaneous screening of multiple LSD and normalizing measured enzyme activity or protein levels against other lysosomal proteins, enzymes, or enzyme activities. Compounds, reagents, and methods for identifying and quantifying multiple target enzymes and proteins.

Abstract: Interative, preferably computer based iterative processes for generating synthetic compounds with desired physical, chemical and/or bioactive properties, i.e., active compounds, are provided. During iterations of the processes, a target nucleic acid sequence is provided or selected, and a library of candidate nucleobase sequences is generated in silico according to defined criteria. A “virtual” oligonucleotide chemistry is chosen and a library of virtual oligonucleotide compounds having the selected nucleobase sequences is generated. These virtual compounds are reviewed and compounds predicted to have particular properties are selected. The selected compounds are robotically synthesized and are preferably robotically assayed for a desired physical, chemical or biological activity. Active compounds are thus generated and, at the same time, preferred sequences and regions of the target nucleic acid that are amenable to oligonucleotide or sequence-based modulation are identified.